1-methyl-4-phenyl-N-(phenylmethyl)-4-piperidinecarboxamide | 279253-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-methyl-4-phenyl-N-(phenylmethyl)-4-piperidinecarboxamide
• 英文别名: N-benzyl-1-methyl-4-phenylpiperidine-4-carboxamide
• CAS: 279253-97-3
• 化学式: C₂₀H₂₄N₂O
• 分子量: 308.423
• InChiKey: YMTDYTRPWSBXLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-methyl-4-phenyl-N-(phenylmethyl)-4-piperidinecarboxamide 在 氯化亚砜 作用下， 反应 1.0h， 以100%的产率得到N-[chloro(1-methyl-4-phenyl-4-piperidinyl)-methylene]benzenemethanamine monohydrochloride
  参考文献：
  名称：

  Antihistaminic spiro compounds

  摘要：

  这项发明涉及到式的化合物 或其前药、N-氧化物、加成盐、季铵盐或其立体化异构体，其中R 1 ，R 2 ，—A—B—，L和n的含义如描述中所给出。该发明涉及到所述化合物的制备和组合物，以及它们作为药物的用途。

  公开号：

  US20050026901A1
• 作为产物：
  描述：

  1-methyl-4-phenyl-4-piperidinecarbonyl chloride 、 苄胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以95%的产率得到1-methyl-4-phenyl-N-(phenylmethyl)-4-piperidinecarboxamide
  参考文献：
  名称：

  Antihistaminic spiro compounds

  摘要：

  这项发明涉及到式的化合物 或其前药、N-氧化物、加成盐、季铵盐或其立体化异构体，其中R 1 ，R 2 ，—A—B—，L和n的含义如描述中所给出。该发明涉及到所述化合物的制备和组合物，以及它们作为药物的用途。

  公开号：

  US20050026901A1

文献信息

• [EN] ANTIHISTAMINIC SPIRO COMPOUNDS<br/>[FR] COMPOSES SPIRO ANTIHISTAMINIQUES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2000037470A1

  公开（公告）日：2000-06-29

  This invention concerns the compounds of formula (I) a prodrug, a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R1 is hydrogen, C¿1-6?alkyl, halo, formyl, carboxyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, N(R?3R4¿)C(=O)-, N(R3R4)C(=O)N(R5)-, ethenyl substituted with carboxyl or C¿1-6?alkyloxycarbonyl, or C1-6alkyl substituted with hydroxy, carboxyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, N(R?3R4¿)C(=O)-, C¿1-6?alkylC(=O)N(R?5¿)-, C¿1-6?alkylS(=O)2N(R?5¿)- or N(R3R4)C(=O)N(R5)- wherein each R3 and each R4 independently are hydrogen or C¿1-4?alkyl, and R?5¿ is hydrogen or hydroxy; R2 is hydrogen, C¿1-6?alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, N(R?3R4¿)C(=O)-, aryl or halo; n is 1 or 2; -A-B- represents a bivalent radical of formula -Y-CH=CH-, -CH=CH-Y-, or -CH=CH-CH=CH-, wherein each hydrogen atom may independently be replaced by R6 wherein R6 is C¿1-6?alkyl, halo, hydroxy, C1-6alkyloxy, ethenyl substituted with carboxyl or C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, formyl, carboxyl or hydroxycarbonylC1-6alkyl, and each Y independently is a bivalent radical of formula -O-, -S- or -NR?7¿-, wherein R7 is hydrogen, C¿1-6?alkyl or C1-6alkylcarbonyl; Z is a bivalent radical of formula -(CH2)p-, -CH=CH-, -CH2-CHOH-, -CH2-O-, -CH2-C(=O), or -CH2-C(=NOH)-, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their -CH2- moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen; C1-6alkyl; C2-6alkenyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with hydroxy, carboxyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, aryl, aryloxy, cyano or R?8¿HN- wherein R8 is hydrogen, C¿1-6?alkyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl; or L represents a radical of formula -Alk-Y-Het?1¿, -Alk-NH-CO-Het2 or -Alk-Het3 wherein Alk represents C¿1-4?alkanediyl; Y represents O, S or NH; Het?1, Het2¿ and Het3 each represent an optionally substituted heterocycle; for use as a medicine.

  本发明涉及具有式（I）的化合物，它是一种前药、N-氧化物、加成盐、季铵盐或立体化学异构体，其中R1是氢、C1-6烷基、卤素、甲酰基、羧基、C1-6烷氧羰基、C1-6烷基羰基、N（R3R4）C（=O）-、N（R3R4）C（=O）N（R5）-、乙烯基取代的羧基或C1-6烷氧羰基，或C1-6烷基取代的羟基、羧基、C1-6烷氧基、C1-6烷氧羰基、N（R3R4）C（=O）-、C1-6烷基C（=O）N（R5）-、C1-6烷基S（=O）2N（R5）-或N（R3R4）C（=O）N（R5）-，其中每个R3和每个R4独立地是氢或C1-4烷基，而R5是氢或羟基；R2是氢、C1-6烷基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、N（R3R4）C（=O）-、芳基或卤素；n为1或2；-A-B-表示式-Y-CH=CH-，-CH=CH-Y-或-CH=CH-CH=CH-的二价基团，其中每个氢原子可以独立地被R6取代，其中R6是C1-6烷基、卤素、羟基、C1-6烷氧基、乙烯基取代的羧基或C1-6烷氧羰基、羟基C1-6烷基、甲酰基、羧基或羟基羧基C1-6烷基，每个Y独立地是-O-、-S-或-NR7-的式子，其中R7是氢、C1-6烷基或C1-6烷基羰基；Z是式-(CH2)p-、-CH=CH-、-CH2-CHOH-、-CH2-O-、-CH2-C（=O）或-CH2-C（=NOH）-的二价基团，前提是二价基团通过它们的-CH2-部分连接到咪唑环的氮上；其中p为1、2、3或4；L是氢、C1-6烷基、C2-6烯基、C1-6烷基羰基、C1-6烷氧羰基、取代羟基、羧基、C1-6烷氧基、C1-6烷氧羰基、芳基、芳氧基、氰基或R8HN-的C1-6烷基，其中R8是氢、C1-6烷基、C1-6烷氧羰基、C1-6烷基羰基；或L表示式-Alk-Y-Het1，-Alk-NH-CO-Het2或-Alk-Het3，其中Alk表示C1-4烷二基；Y表示O、S或NH；Het1、Het2和Het3各自表示一个可选择取代的杂环；用作药物。
• Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives as selective non-peptide delta opiod agonists with antidepressant and anxiolytic activity
  申请人：Steckler Horst Wolfgang Thomas

  公开号：US20060287345A1

  公开（公告）日：2006-12-21

  The present invention relates to the use of 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives according to Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof as selective non-peptide δ-opioid agonists for use in the prevention and/or treatment of various central nervous system disorders, in particular as selective antidepressant and anxiolytic non-peptide δ-opioid agonists. In particular are claimed compounds according to Formula (I) in which A=B is C═O or SO 2 , X is a covalent bond, R 1 is allyloxy, alkyloxyalkyl, Ar or NR 9 R 10 , wherein R 9 and R 10 each independently are hydrogen or Ar; or A=B and R 1 together form a benzoxazolyl radical; p is zero, R 3 is benzyl optionally substituted with hydroxy, alkyl or alkyloxycarbonyl and R 4 and R 5 each are hydrogen.

  本发明涉及使用公式（I）中的4-苯基-4-[1H-咪唑-2-基]-哌啶衍生物及其药学上可接受的酸或碱盐、其立体化学异构体、互变异构体和N-氧化物形式作为选择性非肽δ-阿片受体激动剂，用于预防和/或治疗各种中枢神经系统疾病，尤其是作为选择性抗抑郁和抗焦虑的非肽δ-阿片受体激动剂。特别地，本发明要求公式（I）中A=B为C═O或SO2，X为共价键，R1为烯丙氧基、烷氧烷基、Ar或NR9R10，其中R9和R10各自独立地为氢或Ar；或者A=B且R1构成苯并噁唑基基团；p为零，R3为苄基，可选择性地取代羟基、烷基或烷氧羰基，而R4和R5各自为氢。
• Novel substituted 4-phenyl-4-&lcub;1h-imidazol-2-yl&rcub;-piperidine derivatives and their use as selective non-peptide delta opioid agonists
  申请人：——

  公开号：US20040260096A1

  公开（公告）日：2004-12-23

  The present invention relates to novel 4-phenyl-4-[ 1 H-imidazol-2-yl]-piperidine derivatives according to Formula (I) 1 the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. In particular are claimed compounds according to Formula (I) in which A=B is C═O or SO 2 , X is a covalent bond, R 1 is alkyloxy, alkyloxyalkyl, Ar or NR 9 R 10 , wherein R 9 and R 10 each independently are hydrogen or Ar; or A=B and R 1 together form a benzoxazolyl radical; p is zero, R 3 is benzyl optionally substituted with hydroxy, alkyl or alkyloxycarbonyl and R 4 and R 5 each are hydrogen. The invention also relates to processes for the preparation of the compounds according to the invention and their use in medicine, in particular as selective non-peptide &dgr;-opioid agonists for use in the treatment of various pain conditions.

  本发明涉及新型 4-苯基-4-&lsqb； 1 H-咪唑-2-基]-哌啶衍生物。 1 其药学上可接受的酸或碱加成盐、其立体化学异构体形式、其同分异构体形式和其 N-氧化物形式。特别是根据式 (I) 所述的化合物，其中 A=B 是 C═O 或 SO 2 X为共价键，R 1 是烷氧基、烷氧基烷基、Ar 或 NR 9 R 10 其中 R 9 和 R 10 各自独立地为氢或 Ar；或 A=B 和 R 1 共同形成一个苯并恶唑基；p 为零，R 3 是任选被羟基、烷基或烷氧羰基取代的苄基，R 4 和 R 5 均为氢。本发明还涉及根据本发明制备化合物的工艺及其在医学中的用途，特别是作为选择性非肽类阿片激动剂用于治疗各种疼痛病症。
• Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage
  申请人：Janssens Eduard Frans

  公开号：US20050004170A1

  公开（公告）日：2005-01-06

  The present invention relates to an agent for reducing ischaemic damage to an organ, in particular to a heart and a brain, pharmaceutical compositions comprising said agent and the use of said agent for the treatment of ischaemic diseases to the heart and the brain. The agent comprises a substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivative according to Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof, the N-oxide forms thereof and the prodrugs thereof. In particular are claimed the compounds according to Formula (I) in which A=B is C═O or SO 2 , X is a covalent bond, R 1 is alkyloxy, alkyloxyalkyl, Ar or NR 9 R 10 , wherein R 9 and R 10 each independently are hydrogen or Ar; or A=B and R 1 together form a benzoxazolyl radical; p is zero, R 3 is benzyl optionally substituted with hydroxy, alkyl or alkyloxycarbonyl and R 4 and R 5 each are hydrogen. The use of said agents has important clinical ramifications with regard to the reduction of ischaemic damage to an organ in a mammal, in particular to a heart and/or a brain, the prevention of coronary artery diseases in a mammal by inducing a cardioprotective effect and the treatment and prevention of stroke.

  本发明涉及一种减少器官（尤其是心脏和大脑）缺血性损伤的制剂、包含所述制剂的药物组合物以及使用所述制剂治疗心脏和大脑缺血性疾病的方法。所述制剂包括符合式 (I) 的取代的 4-苯基-4-[1H-咪唑-2-基]-哌啶衍生物 其药学上可接受的酸或碱加成盐、其立体化学异构体形式、其同分异构体形式、其 N-氧化物形式和其原药。特别是根据式 (I) 所述的化合物，其中 A=B 是 C═O 或 SO 2 X为共价键，R 1 是烷氧基、烷氧基烷基、Ar 或 NR 9 R 10 其中 R 9 和 R 10 各自独立地为氢或 Ar；或 A=B 和 R 1 共同形成一个苯并恶唑基；p 为零，R 3 是任选被羟基、烷基或烷氧羰基取代的苄基，R 4 和 R 5 均为氢。上述制剂的使用在以下方面具有重要的临床意义：减少哺乳动物器官的缺血性损伤，特别是心脏和/或大脑；通过诱导心脏保护作用预防哺乳动物的冠状动脉疾病；治疗和预防中风。
• ANTIHISTAMINIC SPIRO COMPOUNDS
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP1144411A1

  公开（公告）日：2001-10-17